TABLE 1.
Demographics, clinical characteristics and outcome of patients and historical controls
| Characteristic | Control group (n = 40) | Syndromic PCR group (n = 79) | P value |
|---|---|---|---|
| Age | 68 (20–86) | 69 (22–87) | 0.62 |
| Sex | |||
| Male Sex (%) | 82.5 (n = 33) | 67.1 (n = 53) | 0.08 |
| Type of Pneumonia | |||
| VAP | 57,5% (n = 23) | 69,62% (n = 55) | 0.22 |
| Apache II | 26 (10–41) ± 6.5 | 26 (7–45) ± 7.8 | 0.78 |
| SOFA | 11 (6–14) ± 2.8 | 11 (7–21) ± 2.9 | 0.77 |
| Days of Hospitalization | 17 (3–120) ± 19.63 | 17 (3–54) ± 11.4 | 0.31 |
| Outcome | |||
| Improvement | 67.5% (n = 27) | 78.48% (n = 62) | 0.26 |
| No change | 12.5% (n = 5) | 1.27% (n = 1) | 0.02 |
| Death | 20% (n = 8) | 20.25% (n = 16) | >0.99 |
| Underlying disease | |||
| COPD | 20% (n = 8) | 21.52% (n = 17) | >0.99 |
| Arterial Hypertension | 42.5% (n = 17) | 56.96% (n = 45) | 0.17 |
| Diabetes Mellitus | 22.5% (n = 9) | 29.11% (n = 23) | 0.52 |
| Heart Failure | 20% (n = 8) | 31.65% (n = 25) | 0.2 |
| Liver Disease/Failure | 7.5% (n = 3) | 5.06% (n = 4) | 0.69 |
| Renal Disease/Failure | 7,5% (n = 3) | 15,19% (n = 12) | 0.38 |
| Hematological Diseases | 0 | 5.06% (n = 4) | 0.3 |
| Cancer | 7.5% (n = 3) | 10.13% (n = 8) | 0.75 |
| Neurological Diseases | 22.5% (n = 9) | 15.19% (n = 12) | 0.32 |
| Drug Abuse | 0 | 1.27% (n = 1) | >0.99 |
| Alcohol | 5% (n = 2) | 2.53% (n = 2) | 0.6 |
| Obesity | 5% (n = 2) | 1,27% (n = 1) | 0.26 |
| No other comorbidity | 30% (n = 12) | 10.13% (n = 8) | 0.0092 |
| HIV | 2.5% (n = 1) | 0 | 0.34 |
| Unknown | 0 | 3.80% (n = 3) | 0.55 |
| Other immunodeficiency | 0 | 5.06% (n = 4) | 0.3 |
| Bed-days | 14 (2–14) ± 2.83 | 9 (1–14)+4.13 | 0.001 |
| Time to diagnosis | 72 (10.88–169.07) ± 38.26 | 3.5 (2.92–4.2) ± 0.3 | <0.0001 |